The LPI participated for the first time at this year’s AMR Conference in Basel on March 3rd and 4th. Joint by networks and companies from Jena and Thuringia, the LPI presented itself as translation center for clinically relevant innovations that support the fight against antimicrobial resistances.
At the 10th anniversary of the AMR Conference in Basel, the LPI experienced two days full of insightful talks, distinguished panel discussions and great networking. Annually, the conference attracts an international, primarily European audience out of start-ups, small and large enterprises, science, investors, and public institutions to collectively deal with the problems of antimicrobial resistances (AMR). The event focuses on innovative approaches and antimicrobial substances, as well as strategies and obstacles in the advancements of diagnostics and therapies against AMR.
For the LPI, the AMR Conference served as an ideal platform to showcase the translation center on an international stage and continue building a network. The core components of the LPI are the First-in-Patient Unit (FiPU) and the centralization of the LPI within the planned laboratory building. The FiPU is currently of particular interest: Starting in 2027, a reconstructed section of the Intensive Care Unit at Jena University Hospital will be available for on-site sample processing, monitoring, and therapeutic adjustments for patients, with laboratory spaces located right next to the treatment rooms. A selection of point-of-care pilot projects will begin clinical validation next year.
Currently, the LPI operates decentralized and is actively expanding network contacts and partnerships – the AMR Conference provided an opportunity to connect with interested people and companies for whom the LPI’s infrastructure is of great importance, as well as to explore potential collaborations with other networks and service partners. Together with the InfectoGnostics Research Campus for public-private partnerships and the research alliance Leibniz Health Technologies, the LPI offered insight into rapid and cost-effective diagnostics for infectious diseases and medical patient care.
The talk sessions covered a broad spectrum of topics: From scientific innovations, to increasing the public awareness of AMR via musicals, to regulations and production processes in the European medical market. Panel discussion allowed for deeper insights into the issues from different angles. In the start-up pitch organized by INCATE, young companies and spin-offs showed their concepts and plans – in future, the LPI will be available, too, to incubate such projects and support their paths to medical application. The LPI also connected with the incubator INCATE itself for joint perspectives.
The conference made clear how much we can accomplish together against AMR. The LPI joins the goal of advancing diagnostic technologies and therapeutic treatments to fight AMR and accelerates their development into clinical practice within its translation infrastructure. International, multidisciplinary cooperation brings lifesaving ideas to where they are needed – with the patients.
We would like to thank all familiar and new faces for the pleasant exchanges and productive conversations. Thanks to our booth partners at InfectoGnostics Research Campus and Leibniz Health Technologies, as well as Innovativ Thüringen, SMA Development, Dynamic42 and Applyo Jena for the joint presence.
We are excited to meet again at the AMR Conference 2027!
Pictures: LPIgGmbH / Sarah Krautwurst // AMR Conference, Basel, March 03-04, 2026
